文献速递银屑病与炎症性皮肤病

Tildrakizumab停药后中重度银屑病患者复发时间的64周事后分析

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-11-05

该事后分析基于reSURFACE 1试验64周数据,纳入第28周达到PASI 75且随机转为安慰剂的银屑病患者。结果显示,停用Tildrakizumab后PASI 75应答丧失的中位时间为5-6个月,BMI增加和病程延长与复发风险升高相关。

要点

  • 停用Tildrakizumab后PASI 75丧失中位时间5-6个月,不因剂量而异
  • 约20%患者36周内未复发(维持PASI 75或失访)
  • BMI增加和病程延长是复发独立预测因素

核心结论

  • Tildrakizumab停药后能提供持久的疗效维持,PASI 75应答丧失中位时间约5-6个月,与剂量无关。
  • BMI增加和病程延长与复发风险升高相关,提示干预可改变的危险因素可能改善个体化长期管理。

研究设计与样本

  • reSURFACE 1试验的64周3期事后分析,纳入成人中重度斑块状银屑病患者。
  • 第28周PASI 75应答者(Tildrakizumab 100或200mg)随机转为安慰剂,随访至第64周。
  • 主要定义为PASI 75应答丧失,敏感性分析包括PASI 90丧失和绝对PASI<2应答丧失。

主要发现

  • 从第28周起,PASI 75/PASI 90/PASI<2应答丧失的中位时间:100mg组分别为142/111/112天,200mg组分别为172/140/113天(均无显著性差异)。
  • 约20%患者在36周期间未复发(维持PASI 75应答或失访)。
  • BMI增加与PASI 75丧失风险相关(HR 1.0345,95%CI 1.0112-1.0582),病程延长亦相关(HR 1.0151,95%CI 1.0028-1.0275)。

关键数值与推荐

  • 复发主要定义为PASI 75应答丧失;敏感性分析采用PASI 90丧失和绝对PASI<2应答丧失。
  • 应答者定义为第28周达到PASI 75改善。

临床怎么用

  • 临床中断治疗时,可预期PASI 75应答维持约5-6个月,不因剂量调整。
  • 对于BMI较高或病程较长的患者,停药后复发风险可能更高,需加强监测。

局限性

  • 事后分析性质,样本来自单一试验。
  • 约20%患者失访或未复发,可能影响复发率估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As treatment interruptions occur during psoriasis management in clinical practice, it is important to know the duration of clinical response after treatment withdrawal. OBJECTIVES: To report time to and predictors of relapse in patients who were tildrakizumab 100 and 200 mg responders (≥75% improvement in Psoriasis Area and Severity Index, PASI 75) at week 28 re-randomized to placebo from reSURFACE 1 trial. METHODS: Post hoc analysis of adult patients with moderate-to-severe plaque psoriasis from a 64-week phase 3 trial. Relapse was primarily defined as loss of PASI 75 response. Both relapses defined as loss of PASI 90 and loss of absolute PASI < 2 response were included as sensitivity analyses. PASI 75, PASI 90 and PASI < 2 responders re-randomized to placebo at week 28 and followed up until week 64 were included. The Kaplan-Meier (KM) estimates of the 64-week relapse rate were calculated. The log-rank test to compare KM curves from responders to tildrakizumab 100 and 200 mg was used. Independent predictors of relapse were explored. RESULTS: Median time to loss of PASI 75/PASI 90/PASI < 2 response from week 28 was 142/111/112 days with tildrakizumab 100 mg and 172/140/113 days with tildrakizumab 200 mg, respectively (all not significant). Around 20% of patients did not relapse (either maintained a PASI 75 response or were lost to follow-up) during the 36-week period. Increase in body mass index (BMI) (hazard ratio, HR [95% confidence interval, CI] for loss of PASI 75 response: 1.0345 [1.0112-1.0582]) and increase in disease duration (HR [95% CI]: 1.0151 [1.0028-1.0275] for loss of PASI 75 response) were associated with an increased risk of relapse, regardless of the relapse definition. CONCLUSIONS: When treatment is interrupted, tildrakizumab provides durable maintenance of efficacy with a median time to loss of PASI 75 response of 5-6 months, irrespective of the dose. Interventions on modifiable risk factors for relapse, such as BMI, may improve personalized long-term psoriasis management.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. J Eur Acad Dermatol Venereol. 2020. PMID: 32979235. doi:10.1111/jdv.16964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。